Carcinoma, Squamous Cell Clinical Trial
Official title:
Immunohistochemical Analysis of Melanocytes in Sun-Exposed Skin
Verified date | March 2011 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
The purpose of this study is to estimate and define the mean number, degree of confluence, and depth of penetration of melanocytes in chronically sun exposed skin of the head and neck using Mart-1 immunostains on frozen sections. The study was conducted to confirm whether similar results were found using permanent sections. The present study used hematoxaline and eosin (H&E) staining as well as Mart-1 staining, and included patients from both Mayo Clinic Jacksonville and Rochester.
Status | Completed |
Enrollment | 100 |
Est. completion date | December 2007 |
Est. primary completion date | December 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Participants undergoing Mohs and reconstructive surgery for basal cell and squamous cell carcinoma of the face and neck Exclusion Criteria: - Participants with a history of radiation to the head and neck were excluded. |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The mean number of melanocytes per high power field for Mart-1 was 12.7 in FL and 11.2 in MN. Using H&E, the means were 10.3 and 8.3 for FL and MN respectively. | one year | No | |
Secondary | Evidence of higher means in FL than in MN after adjusting for age and gender (p<0.001 for H&E, p=0.08 for Mart-1) and strong evidence of an increase in observed numbers of melanocytes with use of the Mart-1 stain compared to the H&E stain (p<0.001) | one year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02743832 -
A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
|
N/A | |
Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT00389727 -
Simultaneous Integrated Boost (SIB)- IMRT
|
Phase 2 | |
Recruiting |
NCT02328391 -
STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE
|
N/A | |
Completed |
NCT00534950 -
Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck
|
N/A | |
Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT01362127 -
Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia
|
Phase 2 | |
Completed |
NCT00240682 -
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
|
Phase 2 | |
Terminated |
NCT02254044 -
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
|
Phase 1 | |
Active, not recruiting |
NCT00829192 -
Phase II AK Study in Organ Transplant Patients
|
Phase 2 | |
Completed |
NCT00539630 -
TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN
|
Phase 3 | |
Completed |
NCT00313027 -
Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation
|
N/A | |
Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
Not yet recruiting |
NCT06094829 -
Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
|
||
Recruiting |
NCT04481256 -
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
|
N/A | |
Active, not recruiting |
NCT02664935 -
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02438995 -
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
Terminated |
NCT00673049 -
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
|
Phase 3 |